Small molecule TMPRSS2 inhibitor as nasal spray to prevent and treat COVID-19
- Probiotics may promote tumor progression?
- Taiwan Professor: Big data confirms that the COVID-19 vaccine is ineffective
- Why are the majority of Monkeypox infected people who have sex with men (MSM)?
- Experimental treatment improves skin cancer survival by 25%
- People who get flu vaccine are 40% less likely to develop Alzheimer’s disease
- Depriving women of the right to abortion is a setback for medical health and society
Small molecule TMPRSS2 inhibitor as nasal spray to prevent and treat COVID-19
- How long can the patient live after heart stent surgery?
- More than 500 new drugs for blood diseases are in development
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
Small molecule TMPRSS2 inhibitor as nasal spray to prevent and treat COVID-19.
In a new study in mice, researchers from Cornell University, Sherbrooke University, and the University of British Columbia have found that a small molecule may be able to be sprayed into people’s noses to prevent pre-exposure COVID-19 disease, if treated shortly after infection with the coronavirus SARS-CoV-2, may provide early treatment.
The relevant research results were published online in the journal Nature on March 28, 2022, with the title “A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic”.
The authors used experimental mice genetically engineered to express a human receptor on the cell surface that binds SARS-CoV-2 and found that the small molecule, called N-0385, inhibited the entry of the coronavirus into mice. cell. They demonstrated that as a TMPRSS2 inhibitor, N-0385 protected mice from infection prior to exposure, while delivering effective treatment within 12 hours of exposure.
Ketobenzothiazole-based peptidomimetics are potent TMPRSS2 inhibitors. Image via Nature, 2022, doi:10.1038/s41586-022-04661-w.
This broad-spectrum therapy was tested in mice exposed to the first SARS-CoV-2 strain detected in Washington state in 2020, as well as the Delta strain, but not the Omicron variant, although These authors are optimistic that it will continue to work.
The authors delivered the small molecule intranasally into mice before, during, and/or after infection with SARS-CoV-2. They tracked the mice’s weight — because weight loss is a signal of infection and a good indicator of disease — and other clinical and pathological markers, such as temperature and mortality, and performed tissue analyses of the mice , to see how they respond.
The therapy prevented the mice from losing weight before they were exposed to the coronavirus, and also prevented death after infection.
Even within 12 hours of infection, the therapy showed very good efficacy, Aguilar-Carreno said.
References:
Tirosh Shapira et al. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature, 2022, doi:10.1038/s41586-022-04661-w.
Small molecule TMPRSS2 inhibitor as nasal spray to prevent and treat COVID-19
(source:internet, reference only)
Disclaimer of medicaltrend.org
